Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk A/S NVO reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide ...

Him & Hers announced Thursday that eligible users can now access the full r | Providers can now send prescriptions of Eli ...

Children and adolescents with type 2 diabetes had an improvement in HbA1c at 26 weeks with a once-daily oral GLP-1, according ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

Amazon offers weight loss drug pricing and delivery to about 3,000 cities, including Seattle, and plans on expanding to 4,500 ...

Novo Nordisk's oral GLP-1 pill achieved its main target in a late-stage diabetes study involving children and adolescents ...

Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ​type 2 diabetes, ...

Asia Pacific is expected to register the highest growth rate during the forecast period. The GLP-1 market, an incretin ...

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

The company's new GLP-1 program will offer both oral and injectable medications Courtesy Amazon Amazon has launched a new GLP ...